June 2026
DMT
What June 2026's 13 new studies found, synthesized from the papers below. All DMT research →
The synthesis
Synthesized from 13 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for DMT, dimethyltryptamine, N,N-DMT, then ranked by relevance.
In June 2026, DMT research spanned pharmacology, biosynthesis, and clinical effects. A randomized trial found that DMT plus harmine increased global brain glucose metabolism by 12.5% in healthy males, and a survey reported some adults with cluster headache use DMT with perceived benefits. However, evidence on endogenous DMT functions remains mixed and contested, and the safety of DMT analogs like 4-Br-DMT appears reduced compared to psilocin and DMT. Overall, findings are preliminary and limited by small samples and lack of long-term outcome data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential. 2026 | narrative review | Mixed | Psychedelics can exacerbate pre-existing psychotic illness and may trigger psychosis in vulnerable individuals, but phenomenological and mechanistic distinctions suggest potential therapeutic applications for carefully selected symptoms in stable patients. | |
| The Architecture of Ego Dissolution: A Mechanical-First Evaluation of N,N-Dimethyltryptamine at the Sigma-1 and 5-HT2A Interfaces 2026 | theoretical | Unclear | The abstract is empty; no findings are reported. | |
| Endogenous N,N-Dimethyltryptamine as a Rigid Mechanical Anchor and Thermodynamic Buffer During Apoptotic Transition 2026 | theoretical | Unclear | The abstract is empty; no findings are reported. | |
| A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine Maintains Neuroplasticity 2026 | theoretical or philosophical paper | Mixed | Proposes that DMT may play a role in maintaining neuroplasticity and that its decline could contribute to age-related loss of cognitive flexibility, but the evidence is mixed and contested. | |
| Synthesis and BiologicalEvaluation of 4‑Bromo-N,N-dimethyltryptamine(4-Br-DMT): A Synthetic BuildingBlock for Future Analog Development 2026 | experimental study | Mixed | 4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT. | |
| Synthesis and Biological Evaluation of 4-Bromo- N,N- dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development 2026 | preclinical study | Mixed | 4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT. | |
| Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation 2026 | physiologically based pharmacokinetic modeling study | Supports | CYP2D6 poor metabolizers showed substantially increased systemic exposure to DMT and harmine compared to normal metabolizers, while ultra-rapid metabolizers showed reduced exposure. | |
| A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine has Endogenous Functions 2026 | theoretical or philosophical paper | Mixed | Argues that evidence for an endogenous physiological function of DMT is mixed and contested, with key findings not independently replicated and receptor affinity mismatches, and that clinical efficacy does not establish endogenous function. | |
| Genome-based optimization of psilocybin and N,N-dimethyltryptamine biosynthetic pathways in E. coli using CRISPR-associated transposases 2026 | experimental study | Supports | ePathIntegrate enabled genome-encoded E. coli strains that produce 1.88 g/L psilocybin and 1.62 g/L DMT, but revealed off-target integrations and mutations that limit the approach. | |
| DMT use in Cluster Headache: Interim Analysis of an International Survey (S23.003) 2026 | survey | Supports | Adults with cluster headache use DMT as a treatment, with some reporting benefits. | |
| Brain-body integromics of the ayahuasca experience. 2026 | within-subject, integrative multiblock partial least squares framework with complementary ¹H-MRS and rCCA analyses | 20 | Supports | Psychedelic states reflect coordinated, system-level interactions between peripheral metabolism and functional brain networks, with subjective experience dimensions linked to specific circulating alkaloids, metabolic alterations, and brain network reconfigurations. |
| Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [18F]FDG-PET study. 2026 | single-blind crossover trial | 14 | Supports | DMT plus harmine increased global cerebral glucose metabolism by 12.5% compared to placebo. |
| Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [ 18 F]FDG-PET study 2026 | single-blind crossover study | 14 | Supports | DMT plus harmine globally increased cerebral glucose metabolism by 12.5% versus placebo, with harmine plasma levels positively correlating with the increase. |
Psychedelics can exacerbate pre-existing psychotic illness and may trigger psychosis in vulnerable individuals, but phenomenological and mechanistic distinctions suggest potential therapeutic applications for carefully selected symptoms in stable patients.
narrative review
The abstract is empty; no findings are reported.
theoretical
The abstract is empty; no findings are reported.
theoretical
Proposes that DMT may play a role in maintaining neuroplasticity and that its decline could contribute to age-related loss of cognitive flexibility, but the evidence is mixed and contested.
theoretical or philosophical paper
4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT.
experimental study
4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT.
preclinical study
CYP2D6 poor metabolizers showed substantially increased systemic exposure to DMT and harmine compared to normal metabolizers, while ultra-rapid metabolizers showed reduced exposure.
physiologically based pharmacokinetic modeling study
Argues that evidence for an endogenous physiological function of DMT is mixed and contested, with key findings not independently replicated and receptor affinity mismatches, and that clinical efficacy does not establish endogenous function.
theoretical or philosophical paper
ePathIntegrate enabled genome-encoded E. coli strains that produce 1.88 g/L psilocybin and 1.62 g/L DMT, but revealed off-target integrations and mutations that limit the approach.
experimental study
Adults with cluster headache use DMT as a treatment, with some reporting benefits.
survey
Psychedelic states reflect coordinated, system-level interactions between peripheral metabolism and functional brain networks, with subjective experience dimensions linked to specific circulating alkaloids, metabolic alterations, and brain network reconfigurations.
within-subject, integrative multiblock partial least squares framework with complementary ¹H-MRS and rCCA analyses Sample size: 20
DMT plus harmine increased global cerebral glucose metabolism by 12.5% compared to placebo.
single-blind crossover trial Sample size: 14
DMT plus harmine globally increased cerebral glucose metabolism by 12.5% versus placebo, with harmine plasma levels positively correlating with the increase.
single-blind crossover study Sample size: 14
Points of agreement
- DMT combined with harmine increases global brain glucose metabolism in healthy volunteers.
- DMT may have therapeutic potential for certain conditions, such as depression and cluster headache, though evidence is preliminary.
- The evidence for endogenous DMT functions is mixed and contested, with key findings not independently replicated.
Conflicts
- One study reports DMT concentrations in the nM range comparable to serotonin and dopamine, while another reports DMT is below detection limit in rat brain.
- Clinical trials show antidepressant effects of DMT, but theoretical papers argue that clinical efficacy does not establish endogenous function.
Gaps
- Long-term durability of DMT effects is not assessed in most studies.
- Most clinical studies have small sample sizes and lack blinding (e.g., single-blind designs).
- Safety and efficacy in diverse populations (e.g., women, clinical patients) are understudied.
- The role of CYP2D6 polymorphisms in real-world ayahuasca use needs validation.
- The safety profile of DMT analogs like 4-Br-DMT requires further investigation.